Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.56 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Molnupiravir SCHEMBL25255890 | 1.00 | P2RY6 (0.56) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| Molnupiravir SCHEMBL21345150 | 1.00 | P2RY6 (0.56) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| Molnupiravir SCHEMBL25922035 | 1.00 | P2RY6 (0.56) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL22387175 | 0.92 | P2RY6 (0.54) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL22387095 | 0.92 | P2RY6 (0.54) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL23762443 | 0.92 | P2RY6 (0.47) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL24780254 | 0.91 | P2RY6 (0.55) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL21345106 | 0.90 | P2RY6 (0.52) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL23762552 | 0.90 | P2RY6 (0.52) | P2RY6P2RY2P2RY4P2RY14NT5E | |
| SCHEMBL22387158 | 0.90 | P2RY6 (0.55) | P2RY6P2RY2P2RY4P2RY14NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255957-A1 | VIRAL ENTRY INHIBITORS AND RNA POLYMERASE INHIBITORS | SELVA THERAPEUTICS, INC. | 2023-08-17 | — | — | US | disclosed |
| WO-2023115220-A1 | DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023106963-A1 | NOVEL CRYSTALLINE FORM OF [(2R,3S,4R,5R)-3,4-DIHYDROXY-5-[4-(HYDROXYAMINO)-2-OXOPYRIMIDIN-1-YL]OXOLAN-2-YL]METHYL-2-METHYLPROPANOATE | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ПРОМОМЕД РУС" | 2023-06-15 | — | — | WO | disclosed |
| WO-2023106964-A1 | NOVEL CRYSTALLINE FORM OF [(2R,3S,4R,5R)-3,4-DIHYDROXY-5-[4-(HYDROXYAMINO)-2-OXOPYRIMIDIN-1-YL]OXOLAN-2-YL]METHYL-2-METHYLPROPANOATE | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ПРОМОМЕД РУС" | 2023-06-15 | — | — | WO | disclosed |
| WO-2022150584-A1 | NON-COVALENT INHIBITORS OF THE MAIN PROTEASE OF SARS-COV-2 AND METHODS OF USE | YALE UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255957-A1 | VIRAL ENTRY INHIBITORS AND RNA POLYMERASE INHIBITORS | POLRMT, POLR2E, POLR2H | P2RY6 3037/4885P2RY2 2983/4885P2RY4 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.